External validation of biomarkers for immune-related adverse events after immune checkpoint inhibition

URN to cite this document:: urn:nbn:de:bvb:355-epub-530922
DOI to cite this document:: 10.5283/epub.53092

Glehr, Gunther

; Riquelme, Paloma ; Yang Zhou, Jordi ; Cordero, Laura ; Schilling, Hannah-Lou ; Kapinsky, Michael ; Schlitt, Hans J. ; Geissler, Edward K. ; Burkhardt, Ralph

; Schmidt, Barbara ; Haferkamp, Sebastian ; Hutchinson, James A. ; Kronenberg, Katharina

License: Creative Commons Attribution 4.0
PDF - Published Version
(3MB)

Date of publication of this fulltext: 21 Oct 2022 10:37

Alternative links to fulltext:DOI Publisher Publisher

Details

Preview

Indexed in

Export bibliographical data

Abstract

Immune checkpoint inhibitors have revolutionized treatment of advanced melanoma, but commonly cause serious immune-mediated complications. The clinical ambition of reserving more aggressive therapies for patients least likely to experience immune-related adverse events (irAE) has driven an extensive search for predictive biomarkers. Here, we externally validate the performance of 59 previously ...